Project Grant R43EY034800
- The National Eye Institute (NEI) awarded a Project Grant of $305,853 to Bluebird Photonics, Inc. under the Vision Research federal grant program (CFDA 93.867) to develop a novel light source for robust multi-MHz retinal optical coherence tomography (OCT). The project aims to enable next-generation OCT technology that can provide diagnostic screening and visualization of both the central and peripheral retinal areas through a roughly 50-fold increase in imaging speed. This advancement is...
- This Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) provides $375,000.00 to Carnegie Mellon University to develop the first ultrasonically-enhanced swept source optical coherence tomography (UESS-OCT) system. The project aims to utilize the interaction between ultrasound waves and light to enable non-invasive, high-resolution optical imaging of tissue structure and function over an extended depth range. The key objectives are to: (1) achieve...
- This Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) will support the development of an ultrasonically-enhanced swept source optical coherence tomography (UESS-OCT) system for label-free, non-invasive optical imaging inside the human body. The $425,000 award to the Regents of the University of California at Riverside will fund research to utilize ultrasound waves to focus and steer light through tissue, enabling high-resolution structural and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Lightfinder Inc. aims to develop a silicon photonic optical coherence tomography (OCT) imager for pathology diagnostics. The primary objective is to create a high-performance, portable, and cost-effective imaging solution by integrating all optical components onto a single silicon chip. The research will address key technical challenges such as achieving high...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop and validate a novel Adaptive Optics Optical Coherence Tomography (AO-OCT) system tailored for high-resolution, wide-field retinal imaging in small animal models, specifically mice. The $305,000 project, awarded on September 1, 2025, with an expected completion date of August 31, 2026, has two key objectives: Develop and optimize a portable AO-OCT system with enhanced imaging capabilities...
- This Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) in the amount of $400,000.00 will fund the development of a new high-speed 3D dynamic contrast microscopic optical coherence tomography (3D DYC-μOCT) system. This advanced label-free imaging technology aims to provide a clearer picture of how airway cells function in health and disease by enabling the 3D visualization of ciliary beating dynamics in human airway organoids without the need for...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $566,288 to Intelon Optics, Inc. to develop a next-generation Brillouin Optical Scanner System (BOSS) with improved speed, accuracy, and sensitivity compared to the current commercial-grade product. The objective is to translate the University of Maryland's Brillouin research technology into a novel BOSS device that can clearly differentiate mild-to-moderate keratoconus and subclinical keratoconus...
- The National Eye Institute (NEI) awarded a $256,296 Project Grant (CFDA 93.867 - Vision Research) to The General Hospital Corporation (Massachusetts General Hospital) to develop new "Auto-Sensing, Instantaneous Adaptive Ranging Optical Coherence Tomography (OCTA)" technology. This technology aims to expand the imaging depth range of OCTA systems, enabling improved visualization of the critical peripheral retinal microvasculature. The project will leverage advances in integrated...
- This SBIR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $304,998 to support the development of a novel visible-light phase shifter and intraocular lens to improve vision for those with age-related macular degeneration. The project aims to create an energy-efficient, small-form factor optical phased array in an implantable intraocular device capable of electronically adjusting and shifting...
- This $305,000 Small Business Innovation Research (SBIR) Phase I project, awarded by the National Science Foundation (NSF) through its Technology, Innovation, and Partnerships (CFDA 47.084) program, is developing innovative metasurface optical waveguiding devices (MOWGs) that control light on a sub-wavelength level. The goal is to overcome the limitations of traditional optical systems, such as weight, size, scalability, and cost, by replacing conventional optical components like lenses and...
EXTRAORDINARY DISPERSION ENGINEERING IN ENABLING ULTRAFAST SWEPT SOURCE VISIBLELIGHT OPTICAL COHERENCE TOMOGRAPHY - PROJECT SUMMARY THIS SBIR PHASE 1 PROJECT FOCUSES ON DEVELOPING, CHARACTERIZING, AND VALIDATING A NEW SWEPT-SOURCE LASER SYSTEM TO ENABLE THE NEXT-GENERATION CLINICAL VISIBLE-LIGHT OPTICAL COHERENCE TOMOGRAPHY (VIS-OCT). WE WILL DEVELOP A NOVEL DESIGN OF PHOTONIC BANDGAP FIBER THAT COMPRISES FIBER BRAGG GRATING ARRAY TO TEMPORALLY DISPERSE BROADBAND PICOSECOND-PULSES TO CREATE A WAVELENGTH SWEEPING PULSE TRAIN. THE NEW SWEPT SOURCE CAN OPERATE UP TO TENS OF MHZ FREQUENCIES WITHOUT MECHANICAL MOVING PARTS, ENABLING ULTRA-HIGH-SPEED SWEPT-SOURCE VIS-OCT (SS-VIS-OCT) FOR THE FIRST TIME. THE NEW LIGHT SOURCE WILL ALSO ENABLE TRULY SHOT-NOISE-LIMITED PERFORMANCE IN VIS-OCT WHILE MITIGATING THE ARTIFACTS CAUSED BY BOTH EYE MOTIONS AND FRINGE WASHOUT. DURING THE PROJECT PERIOD, WE WILL DESIGN, FABRICATE, AND OPTIMIZE THE NEW SWEPT-SOURCE LASER TO ACHIEVE THE DESIRED SWEEPING FREQUENCY, BANDWIDTH, AND PHASE STABILITY. WE WILL FURTHER DEVELOP A PROTOTYPE SS-VIS-OCT AND FULLY TEST ITS PERFORMANCE IN PHANTOM EYEBALLS, EX VIVO BOVINE EYES, AND BLOOD VESSEL PHANTOMS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/30/25 | ||
| Not listed | $253.0k | 5/23/23 |